More than half of the known natural products with antimicrobial, antitumour or antiviral activity are of bacterial origin.

The new materials-based strategies can deliver immunotherapies to specific organ systems and, at least in preclinical models, elicit more controlled and prolonged antitumour responses.

An indirect way of preventing antitumour T-cell responses is by the generation of an immunosuppressive environment.